In this issue of Cardiovascular Revascularization Medicine, Dokollari and colleagues outline their center experience with isolated sutureless aortic valve replacement (AVR) with the Perceval bioprosthesis (Corcym Corporation) in 101 patients and include a subgroup propensity-adjusted analysis in patients undergoing redo-AVR [ ]. The experience included patients from a single center from 2013 to 2020. The average patient age was 71.2 ± 7.6 years, 54.4 % were male, and the mean EuroScore II was 3.5 ± 4.5. Mean cardiopulmonary bypass (CPB) time was 65 min with 47 min of aortic occlusion; valve re-deployment was required in 9.9 % of cases. Mean aortic gradient following sutureless AVR was 14.7 ± 4.0 mmHg, mild paravalvular lead in 2.0 % and trace in 7.0 %. While in the hospital, 8.0 % of patients required permanent pacemaker insertion and 3.0 % of patients had a stroke. Early re-operation for bleeding occurred in 9.0 % and there were 2 in-hospital deaths (2.0 %). Patients were followed up to 7 years following discharge with mean follow-up of 1.5 years, during this time period 10.1 % had stroke and 17.2 % had hospital re-admission. Independent risk factors for late death included female sex and diastolic dysfunction (grade ≥ 2).